GlassScriptPhysician profile
Meenu Gupta
NPI 1831155522
$3,899.71
in general payments reported to CMS, 2019-2025
30 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $257 · 2021: $570 · 2022: $507 · 2023: $560 · 2024: $440 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $837.02 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $476.90 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $381.21 | 2019-2024 | Tezspire |
| Lilly USA, LLC | $334.06 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $311.49 | 2019-2025 | |
| Madrigal Pharmaceuticals | $183.71 | 2025 | Rezdiffra |
| Novo Nordisk INC | $146.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.84 | 2019-2025 | Jardiance |
| Galderma Laboratories, L.P. | $125.00 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $125.00 | 2024 | Ruconest |
| Procept Biorobotics Corporation | $117.26 | 2023 | Aquabeam Robotic System |
| Bayer Healthcare Pharmaceuticals INC. | $106.92 | 2021-2025 | |
| Genzyme Corporation | $98.33 | 2025 | |
| Novartis Pharmaceuticals Corporation | $65.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.30 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $47.88 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.95 | 2025 | Xifaxan |
| Dexcom, INC. | $41.16 | 2022-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $35.89 | 2025 | Aptima |
| Lexicon Pharmaceuticals, INC. | $28.88 | 2023 | Inpefa |
| Hologic INC | $27.01 | 2019 | |
| Abbott Laboratories | $23.81 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.08 | 2024 | Voquezna |
| Almatica Pharma LLC | $22.66 | 2023 | Sertraline Hcl, Gralise, Loreev Xr |
| Optinose US, INC. | $22.47 | 2025 | |
| Boston Scientific Corporation | $21.55 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.38 | 2023 | Eliquis |
| Esperion Therapeutics, INC. | $19.63 | 2024 | Nexletol |
| Abbvie INC. | $18.89 | 2025 | |
| Arbor Pharmaceuticals, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meenu Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.